Openbookopenbook
Equity
Regenxbio Inc(RGNX)
USD --+0.00%
Reward48Moderate
Risk70High
📊75%Data
Thin -110% profit margin · Revenue growing 23% YoY
RGNX
+0.0 · +0.00%
USD · NASDAQ
Regenxbio Inc | Healthcare
Value Trap
Market Cap:457.63M
ℹ️
Reward Rating
48
Moderate
Bottom 25% (model universe)
75% data coverage
ℹ️
Risk Rating
70
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on RGNX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $28.45.

What is Regenxbio Inc?

, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.

RGNX · Verdict

Moderate reward · elevated risk

RGNX's standout is valuation; cash flow and balance sheet weigh on the picture.

Based on 88% data coverage

RGNX · Verdict

What’s working & what to watch

Strengths 1

  • Valuation83/100

    PEG ratio 0.26

Watchouts 4

  • Cash flow16/100

    -211% free-cash-flow margin

  • Balance sheet26/100

    Current ratio 2.69

  • Profitability32/100

    -273% net margin · -77% ROE

  • Growth42/100

    Revenue -43.8% CAGR

Model-based scoring. For information only — not financial advice.

What is Regenxbio Inc?

, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 457.63M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (48)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap457.63M
P/E RatioN/A
Dividend YieldN/A
52 Week High16.19
52 Week Low5.035
Last AnnualDecember
IPO Date9/17/2015
IncorporatedUSA
Shares Outstanding51M
No. of Employees353
IndustryBiotechnology
ExchangeNASDAQ
Beta1.053
CurrencyUSD
Websitewww.regenxbio.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.